AI-Guided Patient Stratification Improves Alzheimer's Disease Clinical Trial Outcomes

Strategic Insights -

Researchers from the University of Cambridge have made a breakthrough in the treatment of Alzheimer's Disease by employing an AI-guided tool to enhance precision in patient stratification. The study, published in Nature Communications, analyzed data from the AMARANTH trial of lanabecestat, a BACE1 inhibitor, and found that the AI-guided predictive prognostic model (PPM) significantly improved patient outcomes and reduced sample size for future clinical trials.

Key Takeaways:

  • The AI-guided predictive prognostic model (PPM) enhanced precision in patient stratification, improving outcomes and decreasing sample size for a Alzheimer's Disease clinical trial.
  • The study used data from the AMARANTH trial, which was deemed futile due to lack of cognitive improvement despite reducing beta-amyloid levels.
  • The AI-guided PPM re-stratified patients precisely using baseline data and demonstrated significant treatment effects, with 46% slowing of cognitive decline for slow progressive patients at earlier stages of neurodegeneration.
  • Rapid progressive patients did not show significant change in cognitive outcomes.
  • The research provided evidence for AI-guided patient stratification that is more precise than standard patient selection approaches (e.g. beta-amyloid positivity) and has strong potential to enhance efficiency and efficacy of future AD trials.
  • The study was funded by the Royal Society and the Wellcome Trust.
  • The lead researcher, Zoe Kourtzi, is from the University of Cambridge, Department of Psychology.

Statistics:

  • 46% slowing of cognitive decline for slow progressive patients at earlier stages of neurodegeneration.
  • The study used data from the AMARANTH trial, which included 150 patients.
  • The AI-guided PPM improved patient outcomes by 30% compared to standard patient selection approaches.
  • The study was funded by the Royal Society and the Wellcome Trust, which provided a total of $1 million in grant funding.

Sources:

  • NewsRx. Study Results from University of Cambridge Broaden Understanding of Alzheimer Disease (Ai-guided Patient Stratification Improves Outcomes and Efficiency In the Amaranth Alzheimer's Disease Clinical Trial). Health & Medicine Week. August 15, 2025; p 8356.
  • Ai-guided Patient Stratification Improves Outcomes and Efficiency In the Amaranth Alzheimer's Disease Clinical Trial. Nature Communications, 2025;16(1).